Reading WHWK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.

QuarterlyIQ Insights · WHWK

News & Events

Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.

Type

Direction

10 matches

2026-05-13Item 3.02
WHWK — capital allocation — Unregistered Sales of Equity Securities The information in
Unregistered Sales of Equity Securities The information in
Capital allocationnegative
2026-05-13Item 1.01
WHWK — M&A activity — Entry into a Material Definitive Agreement Securities Purchase Agreement
Entry into a Material Definitive Agreement Securities Purchase Agreement On May 12, 2026, Whitehawk Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers named therein (the “PIPE Investors”), pursuant to which the Company agreed to sell to the PIPE Investors (i) 4,330,866 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $3.92 per share, and (ii) 17,991,021…
M&A activitypositive
2026-05-13Item 7.01
WHWK — litigation filed
of this Current Report on Form 8-K, including the information incorporated by reference from Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act. Forward Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectatio…
Legal / regulatorylitigation filednegative
2026-05-07Item 2.02
WHWK — earnings in line
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Earnings preannouncementearnings inlineneutral
2026-03-12Item 2.02
WHWK — earnings beat
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Earnings preannouncementearnings beatpositive
2025-11-06Item 2.02
WHWK — earnings beat
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Earnings preannouncementearnings beatpositive
2025-08-07Item 2.02
WHWK — earnings miss
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Earnings preannouncementearnings missnegative
2025-05-08Item 2.02
WHWK — earnings beat
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Earnings preannouncementearnings beatpositive
2025-03-18Item 2.02
WHWK — earnings miss
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Earnings preannouncementearnings missnegative
2025-03-04Item 1.01
WHWK — private placement
Entry into a Material Definitive Agreement. Registration Rights Agreement On March 4, 2025, Aadi Bioscience, Inc. (the “ Company ”) consummated its previously announced private placement (the “ PIPE Financing ”). At the closing of the PIPE Financing, the Company entered into a Registration Rights Agreement (the “ Registration Rights Agreement ”) with the purchasers in the PIPE Financing. Pursuant to the Registration Rights Agreement, the Company will prepare and file a resale registration sta…
Capital allocationprivate placementneutral

Coming next

General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.